Chronic relapsing-remitting inflammatory conditions of the gastrointestinal tract characterized by loss of immune tolerance to commensal gut microbiome. Comprises two main entities: Crohn's disease (transmural inflammation affecting any GI segment, typically terminal ileum) and Ulcerative Colitis (continuous mucosal inflammation limited to colon, spreading proximally from rectum). Results from complex interplay between genetic susceptibility (>200 risk loci), gut barrier dysfunction, dysbiosis, and dysregulated immune responses.
Think of your gut lining as a gated apartment complex where the security system has catastrophically failed. Normally, the doormen (gut barrier with tight junctions) recognize friendly residents (gut microbiome commensals) and keep them in the courtyard (lumen), while carefully screening what enters the building (bloodstream). In IBD, three disasters happen simultaneously: (1) the gates develop permanent cracks (leaky gut via zonulin upregulation), (2) some friendly residents turn into troublemakers (dysbiosis with pathobiont expansion), and (3) the security guards (immune system) lose their training manual (immunogram dysfunction) and start attacking everyone—residents and building structure alike. The guards can't distinguish friend from foe because their pattern-recognition software (NOD2, ATG16L1) has corrupted code. In Crohn's, the guards blow holes through entire walls (transmural inflammation, fistulas); in UC, they systematically destroy just the lobby floors (mucosal inflammation) starting at the entrance (rectum) and working their way up. The building superintendent (Treg cells) who should calm everyone down is either absent or ignored, while inflammatory alarm bells (TNF-α, IL-23, IL-17) keep ringing nonstop, recruiting more aggressive security (Th17 cells) in a self-perpetuating crisis.
IBD pathogenesis involves five interconnected mechanisms:
1. Genetic Susceptibility
- NOD2 mutations (chromosome 16) → impaired recognition of bacterial muramyl dipeptide → defective autophagy of intracellular bacteria → persistent bacterial antigens
- ATG16L1 variants → compromised autophagy machinery → accumulation of damaged organelles and inflammatory signaling
- IL23R polymorphisms → enhanced IL-23 signaling → sustained Th17 differentiation
-
200 additional risk loci affect barrier function, microbial sensing, and immune regulation
2. Barrier Dysfunction
3. Dysbiosis Pattern
- Loss of protective species: Faecalibacterium prausnitzii (major butyrate producer), Bacteroides, Bifidobacteria
- Expansion of pathobionts: adherent-invasive E. coli (AIEC), Fusobacterium, sulfate-reducing bacteria
- Reduced SCFA production (especially butyrate) → impaired colonocyte energy → barrier weakening
- Altered bile acid metabolism → loss of FXR/TGR5 anti-inflammatory signaling
- Biofilm formation on mucosa → persistent antigenic stimulation
4. Dysregulated Immune Response
graph TD
A[Luminal antigens penetrate barrier] --> B[Dendritic cell activation]
B --> C[Th1 differentiation - Crohn's]
B --> D[Th17 differentiation - both]
C --> E["IFN-γ production"]
E --> F[Macrophage M1 polarization]
F --> G["TNF-α, IL-1β, IL-6 release"]
D --> H[IL-23 drives Th17 expansion]
H --> I[IL-17A, IL-17F, IL-22 production]
I --> J[Neutrophil recruitment]
J --> K[Tissue damage, ROS, proteases]
G --> L[Chronic inflammation cycle]
K --> L
L --> M[Epithelial damage]
M --> A
N[Treg defects] -.inhibits.-> B
N -.fails to suppress.-> D
- Pattern recognition: TLR4 hyperresponsiveness to LPS → NF-κB activation → cytokine storm
- Crohn's (Th1-dominant): IL-12 → IFN-γ → TNF-α → granuloma formation, transmural inflammation
- UC (modified Th2/Th17): IL-23 → IL-17 → neutrophil infiltration, crypt abscesses
- Defective Treg cells: reduced IL-10 and TGF-β production, impaired suppression
- Loss of oral tolerance mechanisms to food antigens and commensals
5. Immunoceptive Learning
6. Tissue Damage Cascade
- Matrix metalloproteinases (MMP-1, MMP-3, MMP-9) → collagen degradation
- Reactive oxygen species → oxidative damage to DNA, lipids, proteins
- Ulceration → bleeding, protein loss, malabsorption
- Stricture formation (Crohn's) → bowel obstruction via chronic fibrosis
- Fistula formation (Crohn's) → abnormal connections between bowel segments or organs
- Continuous inflammation → dysplasia → colorectal Cancer risk (2% at 10y, 8% at 20y, 18% at 30y)
Metamodel Integration:
- Metamodel 1: IBD exemplifies breakdown of immune-microbiome homeostasis and immunoception failure where the brain-immune axis perpetuates disease through learned inflammatory responses
- Metamodel 4: Represents evolutionary mismatch—modern diet, antibiotics, hygiene, and chronic stress incompatible with ancient gut-immune coevolution; absence of "old friends" microbes disrupts tolerance development
Patient Assessment:
- Calprotectin is the primary non-invasive biomarker: >200 μg/g indicates active inflammation requiring treatment escalation (sensitivity 93%, specificity 96% for distinguishing IBD from IBS)
- Values 50-200 μg/g borderline, require clinical correlation with symptoms, CRP, and colonoscopy
- Monitor every 3 months during active disease, every 6-12 months in remission
- CRP elevation in Crohn's (60-70% sensitivity) but often normal in UC (25% sensitivity)
cPNI Treatment Integration:
IBD requires pharmaceutical management (5-ASA, immunomodulators, biologics) but cPNI interventions are crucial adjuncts:
-
Microbiome restoration:
-
Barrier support:
- Butyrate supplementation or production via fiber (if tolerated)
- Zinc 30mg daily → metallothionein induction → tight junction repair
- Vitamin D >30 ng/mL → VDR signaling reduces inflammation
- Glutamine 5-10g BID → enterocyte fuel
-
Stress axis regulation:
-
Dietary modification:
- Specific Carbohydrate Diet or Mediterranean diet show efficacy
- Identify individual triggers (dairy, gluten often problematic even without coeliac)
- Avoid emulsifiers (carboxymethylcellulose) → mucus layer disruption
-
Resolution support:
Biological Therapy Context:
- infliximab (anti-TNF-α): 60-70% initial response but 20-40% lose response annually due to antibody formation or alternative pathway activation
- Anti-IL-12/23 (ustekinumab), anti-integrin (vedolizumab), JAK inhibitors (tofacitinib) for refractory disease
- Fecal Calprotectin predicts relapse 2-3 months before symptoms
Cancer Surveillance:
Colonoscopy screening:
- Start at 8 years for pancolitis, 15 years for left-sided UC
- Every 1-2 years with chromoendoscopy
- Risk stratified by extent, duration, PSC, family history
- Calprotectin >200 μg/g: 93% sensitivity, 96% specificity for active IBD vs IBS
- NOD2 homozygous mutations increase Crohn's risk 20-40× (20-30% of Crohn's patients carry mutations)
-
200 genetic risk loci identified via GWAS; NOD2, IL23R, ATG16L1 most significant
- Global prevalence: 0.3-0.5% in Western populations, rapidly increasing in Asia, Africa (hygiene hypothesis validation)
- Bimodal age distribution: peak onset 15-30 years (70%), secondary peak 50-70 years (30%)
- Crohn's affects mouth-to-anus (any segment), 40% terminal ileum, 30% ileocolic, 25% colonic
- UC always starts in rectum, spreads proximally in continuous fashion (never skip lesions)
- Smoking paradox: protects against UC (50% risk reduction) but doubles Crohn's severity and complications
- Anti-TNF response rates: 60-70% initially, but 23-46% lose response by 12 months (immunogenicity)
- Colorectal cancer risk: 2% at 10 years, 8% at 20 years, 18% at 30 years (cumulative inflammation burden)
- Faecal Calprotectin <50 μg/g has 95% negative predictive value for excluding IBD
- Extraintestinal manifestations: 25-40% develop arthritis, uveitis, PSC, erythema nodosum, pyoderma gangrenosum
- F. prausnitzii depletion severity correlates with relapse risk (protective strain produces anti-inflammatory metabolites)
- Peak cortisol resistance occurs during active flares (inflammatory cytokines → GR phosphorylation → reduced nuclear translocation)
- Calprotectin — primary fecal biomarker >200 μg/g diagnostic for active inflammation
- dysbiosis — core pathogenic mechanism with loss of protective commensals in
- gut barrier — dysfunction via tight junction disruption fundamental to
- leaky gut — increased Intestinal permeability allows antigenic penetration in
- zonulin — mediator of barrier opening elevated in active
- Th17 — pathogenic T helper subset driving IL-17-mediated neutrophil recruitment in
- Th1 — dominant in Crohn's disease producing IFN-γ and driving granuloma formation
- TNF-α — master inflammatory cytokine targeted by biologics in treatment of
- IL-23 — key driver of pathogenic Th17 expansion in both forms of
- IL-17 — pro-inflammatory effector cytokine causing neutrophil infiltration in
- IL-10 — anti-inflammatory cytokine deficient due to Treg dysfunction in
- Treg cells — regulatory T cells fail to suppress inflammation in
- NOD2 — bacterial peptidoglycan sensor gene mutations strongest genetic risk for Crohn's
- ATG16L1 — autophagy gene variants impair bacterial clearance increasing
- Faecalibacterium prausnitzii — depleted butyrate-producer; loss predicts relapse in
- Fusobacterium — invasive pathobiont expanded in active
- butyrate — protective SCFA reduced in due to dysbiosis, impairs colonocyte energy
- SCFA — short-chain fatty acids depleted in active disease contributing to barrier dysfunction
- chronic inflammation — persistent immune activation drives complications and cancer risk in
- autoimmune disease — loss of immune tolerance to self-antigens and commensals characterizes
- immunogram — maladaptive CNS-immune learning perpetuates disease even after trigger removal in
- chronic stress — psychological stress doubles relapse risk through HPA axis in
- glucocorticoid resistance — develops during flares via cytokine-induced GR modification in
- colorectal cancer — risk increases 2% per decade due to chronic inflammation in
- tight junctions — disrupted via zonulin and inflammatory cytokines in
- mucin — protective mucus layer thinned due to goblet cell dysfunction in
- Defensins — antimicrobial peptides reduced in Crohn's due to Paneth cell defects
- Vitamin D — deficiency common and worsens disease; VDR signaling anti-inflammatory in
- NF-κB — master transcription factor driving cytokine production in
- infliximab — anti-TNF biologic achieving 60-70% response rates in treatment of
- Specialized pro-resolving mediators (SPMs) — deficient in active disease; omega-3 supplementation beneficial for
- Module 1 — immunoception and immunogram formation in chronic inflammatory states
- Module 4 — gut barrier dysfunction and microbiome dysregulation